Jounce Therapeutics Inc (NASDAQ:JNCE) Director Barbara Gayle Duncan sold 4,000 shares of the stock in a transaction that occurred on Friday, January 26th. The stock was sold at an average price of $25.00, for a total value of $100,000.00. Following the completion of the sale, the director now owns 4,000 shares in the company, valued at $100,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of Jounce Therapeutics Inc (NASDAQ JNCE) traded up $1.15 during midday trading on Monday, hitting $26.19. The stock had a trading volume of 320,483 shares, compared to its average volume of 343,583. Jounce Therapeutics Inc has a 12-month low of $11.05 and a 12-month high of $29.29. The stock has a market capitalization of $807.43 and a P/E ratio of -124.71.
Jounce Therapeutics (NASDAQ:JNCE) last issued its quarterly earnings results on Monday, November 13th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.12. Jounce Therapeutics had a negative return on equity of 1.39% and a negative net margin of 2.03%. The firm had revenue of $18.10 million for the quarter, compared to the consensus estimate of $20.00 million. Jounce Therapeutics’s revenue was up 7.1% on a year-over-year basis. research analysts expect that Jounce Therapeutics Inc will post -0.86 earnings per share for the current fiscal year.
JNCE has been the topic of several recent analyst reports. Zacks Investment Research downgraded Jounce Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 17th. JPMorgan Chase & Co. set a $28.00 price target on Jounce Therapeutics and gave the stock a “buy” rating in a report on Monday, November 13th. Finally, Robert W. Baird reiterated a “buy” rating and issued a $30.00 price target on shares of Jounce Therapeutics in a report on Friday, November 10th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Jounce Therapeutics presently has an average rating of “Buy” and a consensus price target of $24.00.
ILLEGAL ACTIVITY NOTICE: “Barbara Gayle Duncan Sells 4,000 Shares of Jounce Therapeutics Inc (JNCE) Stock” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/01/29/barbara-gayle-duncan-sells-4000-shares-of-jounce-therapeutics-inc-jnce-stock.html.
About Jounce Therapeutics
Jounce Therapeutics, Inc is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient.
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.